Vanda Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Vanda Pharmaceuticals generated cash of $12,801,000, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore $792,000.
Cash Flow
| 2014 | -81.55M | -12.03M | 89.72M |
|---|---|---|---|
| 2015 | 12.44M | -26.59M | 4.09M |
| 2016 | -8.10M | -10.07M | 7.75M |
| 2017 | -1.98M | -10.10M | 5.25M |
| 2018 | 29.98M | -109.66M | 107.12M |
| 2019 | 45.94M | -68.30M | 6.26M |
| 2020 | 51.77M | -41.49M | 5.63M |
| 2021 | 64.21M | -76.69M | 3.55M |
| 2022 | 31.98M | 49.92M | 734K |
| 2023 | 12.80M | -12.05M | 0 |
VNDA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 135.49M | 52.59M | 61.61M | 45.65M | 61.74M | 34.33M | 40.42M | 50.84M | 60.90M | 64.76M |
Operating activities | ||||||||||
Net income | 2.50M | 6.27M | 33.15M | 23.33M | 115.55M | 25.20M | -15.56M | -18.01M | -39.86M | 20.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.01M | 2.73M | 2.84M | 2.86M | 2.89M | 2.95M | 2.98M | 11.86M | 13.55M | 2.78M |
Stock-based compensation expense | 14.04M | 16.27M | 15.37M | 13.36M | 13.45M | 0 | 10.46M | 8.54M | 7.96M | 5.87M |
| Deferred income tax benefit | 14.04M | 16.27M | 15.37M | 13.36M | 13.45M | 0 | 10.46M | 8.54M | 7.96M | 5.87M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -707K | -1.08M | -2.46M | -3.76M | 2.34M | -11.20M | 2.52M | -4.29M | -12.67M | -1.62M |
Inventories | -771K | -4.47M | -2.23M | -2.87M | -722K | 70K | -1.06M | 200K | 387K | -2.21M |
Accounts payable | -10.98M | 11.79M | 3.04M | 7.82M | 744K | -4.87M | 5.95M | 575K | 9.43M | 174K |
Cash generated by operating activities | 12.80M | 31.98M | 64.21M | 51.77M | 45.94M | 29.98M | -1.98M | -8.10M | 12.44M | -81.55M |
Investing activities | ||||||||||
Purchases Of Investments | -512.60M | -349.25M | -420.46M | -346.62M | -394.51M | -282.39M | -148.13M | -165.40M | -193.11M | -93.34M |
Investments In Property Plant And Equipment | -383K | -679K | -552K | -1.79M | -1.01M | -25.36M | -1.66M | -1.40M | -2.52M | -8.76M |
Acquisitions Net | -100.66M | -50.60M | -12K | -229K | 67.29M | 25M | 0 | 0 | 0 | -8M |
Cash generated by investing activities | -12.05M | 49.92M | -76.69M | -41.49M | -68.30M | -109.66M | -10.10M | -10.07M | -26.59M | -12.03M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 734K | 3.55M | 5.63M | 6.26M | 0 | 5.25M | 0 | 4.37M | 87.31M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -283K | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 0 | 734K | 3.55M | 5.63M | 6.26M | 107.12M | 5.25M | 7.75M | 4.09M | 89.72M |
Net Change In Cash | 792K | 82.90M | -9.02M | 15.96M | -16.09M | 27.41M | -6.79M | -10.41M | -10.05M | -3.86M |
Cash at end of period | 136.29M | 135.49M | 52.59M | 61.61M | 45.65M | 61.74M | 33.62M | 40.42M | 50.84M | 60.90M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |